Winning the Tender Is Not the Same as Winning the Margin
Why sustainable MedTech profitability depends on tender strategy, contract economics, pricing discipline, and execution after the award.
A medical device manufacturer can win a major hospital tender, secure an important account, and expand its installed base.
Six months later, the economics may tell a different story.
The contracted price is lower than the original target. Service and training requirements exceed the assumptions used in the bid. Product mix differs from the forecast. Logistics and support costs accumulate across the life of the agreement.
The tender was won. But was the business?
That is a fundamental question for Medical Devices and MedTech executives. A contract award confirms commercial success against the tender criteria. It does not, by itself, confirm that the supplier will earn an attractive and sustainable return.
Commercial Transformation begins by connecting the decision to bid with the economics of delivering the contract.
A demanding market raises the cost of commercial fragmentation
MedTech Europe's Facts & Figures 2026, published October 6, reports that European medical device market growth slowed to 1.8% in 2025, compared with a ten-year average of 5.6%. The report also highlights pressure on procurement budgets and calls for purchasing models that recognize value beyond acquisition price.
For manufacturers, this environment increases the importance of disciplined choices about where to compete, what value to offer, how to price it, and which commercial commitments can be delivered profitably.
The answer is not to retreat from competition or treat every low-margin contract as a mistake. Some contracts may support legitimate strategic objectives, such as establishing an installed base or developing a long-term customer relationship.
The issue is whether the organization understands the trade-off before making it—and can verify the outcome afterward.
MedTech is not a single commercial business model
Medical Devices includes categories with very different economics.
An implantable device may involve clinical support, consignment inventory, and high-touch account management. Capital equipment can combine an initial placement with maintenance, upgrades, consumables, and multi-year service commitments. In vitro diagnostics may rely on instrument placement and reagent volumes. Other businesses have distributor-led models or recurring software and support components.
These differences matter because invoice price is only one part of account profitability.
To understand the economic value of a tender, management may need to connect:
Contracted and realized net prices, including rebates, discounts, and other commercial concessions.
Expected versus actual product and procedure volumes, mix, and utilization.
Installation, maintenance, clinical training, technical service, and other contractual obligations.
Inventory, delivery, distribution, and working-capital implications.
The cost of serving the account throughout the contract lifecycle.
Not every cost applies to every device or contract. But where these obligations exist, they must be included consistently in the commercial decision.
Without that visibility, organizations may celebrate revenue growth while failing to detect weakening contribution margins.
Pricing excellence starts before the bid is submitted
Many organizations focus pricing governance on the final discount request: what can we offer to win?
A more valuable question comes earlier: under which conditions should we pursue this opportunity at all?
A disciplined bid/no-bid process considers strategic fit, differentiated customer value, competitive position, contract duration, forecast reliability, delivery obligations, and expected economic contribution.
Before committing, leaders should be able to evaluate at least three scenarios: the business case at the proposed terms, the downside case if volume or service assumptions deteriorate, and the conditions that would justify an alternative offer—or walking away.
This is where portfolio strategy, pricing, finance, service operations, and sales need to agree on one set of economic assumptions.
A pricing corridor is useful only when it is connected to contract economics and clear decision rights.
Value-based procurement requires evidence and execution
In Europe, procurement rules do not universally require awards to be based on the lowest initial price. Under Directive 2014/24/EU, public-contract award frameworks can consider price-quality relationships and lifecycle costs, subject to the applicable rules and the published evaluation criteria of each tender.
This creates an opportunity for manufacturers to articulate relevant value—such as clinical performance, service reliability, technical support, and total cost of use—where the procurement framework permits those factors to be evaluated.
But a value proposition is not a substitute for evidence. Nor can sophisticated pricing arguments override a tender's stated criteria.
The commercial task is to translate verified product and service differentiation into compliant, economically sound proposals.
That requires close coordination between medical, regulatory, market access, commercial, finance, and legal functions wherever their input is relevant.
The contract must remain economically visible after the award
For many manufacturers, the largest transparency gap is not at the tender deadline. It appears during contract execution.
The original business case may sit in a bid file. Actual pricing is recorded in a commercial system. Service costs live elsewhere. Consumable volumes appear in the ERP. Contract exceptions are handled locally. Finance sees the overall result, but not always its operational root causes.
When those data remain fragmented, the organization loses the ability to manage the contract as an economic asset.
An effective commercial operating model connects the original assumptions with actual performance: net price realization, volume and mix, cost to serve, contractual obligations, account contribution, and the decisions required to correct deviations.
That visibility must be useful to executives and account teams—not simply another retrospective dashboard.
From tender optimization to Commercial Transformation
At Stratence Partners, we approach these challenges through an integrated framework linking Strategy Optimization, Pricing Excellence, and Commercial Effectiveness, supported by Data Management, Data Science, and Integrated Commercial Systems.
For MedTech organizations, this can translate into five connected priorities:
Portfolio and account strategy. Decide where to compete, which opportunities justify investment, and how customer segments, products, and contract structures affect economic value.
Pricing and contracting governance. Define economic guardrails, approval authority, bid/no-bid logic, and the treatment of commercially justified exceptions.
True profitability transparency. Reconcile gross-to-net revenue with the relevant cost-to-serve drivers so management can assess contract and account contribution consistently.
Commercial execution. Equip teams to negotiate, fulfill, monitor, and renew contracts in line with strategic priorities and compliance requirements.
Integrated data and decision support. Use the Stratence Partners Integrated Ecosystem, SPIE+AI™, to connect trusted data, economic analytics, and disciplined commercial decisions within the existing operating model.
AI Powered capabilities can accelerate data integration, scenario analysis, exception identification, and decision support. They are not a replacement for sound commercial governance or reliable source data.
The objective is to move from diagnosis to implementation, capability transfer, and sustainable autonomy.
Five questions for the leadership team
A practical assessment starts with questions that should be answerable before and after any strategic tender:
Do we know the expected contribution of the full contract, not just its award value?
Can we explain the difference between the approved business case and actual account economics?
Are service and operational commitments visible when pricing decisions are made?
Do sales, finance, pricing, and operations work from consistent assumptions and data?
Can we identify and correct margin erosion early enough to change the outcome?
If these questions require multiple teams, incompatible spreadsheets, and weeks of reconciliation, the underlying issue is larger than tender pricing.
It is a commercial system problem.
The real measure of a winning contract
Medical technology creates value for healthcare systems through innovation, quality, and better care. Commercial excellence helps ensure that manufacturers can deliver that value consistently and sustainably.
Winning a tender matters.
Delivering on its clinical, operational, and financial commitments matters more.
And understanding the full economics—from bid strategy to contract execution—is what allows leadership teams to distinguish profitable growth from activity that merely looks like success.
The strongest MedTech organizations do not simply win more business. They know which business to win, how to deliver it, and how to preserve the value created.
If your organization is reassessing tender economics, account profitability, pricing governance, or commercial execution, we welcome an executive discussion.
Fernando Ventureira CEO | Stratence Partners fventureira@stratence.partners
Stratence Partners Commercial Transformation, AI Powered A Collaborating Firm of Andersen Consulting
Comments